Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Project Leads

Maria Paula Bautista Acelas

Maria Paula Bautista Acelas, Senior Scientific Project Manager, DIA

Vassileva-Maria

Maria Vassileva, Chief Science and Regulatory Officer, DIA

Why This Matters

Cancer treatments are more effective but increasingly complex. Yet there is no universal definition of treatment tolerability in immuno-oncology. Current measures focus on side effects and discontinuation rates, missing critical aspects of patients’ daily lives.

This gap makes it harder for clinicians and patients to make informed decisions and limits regulators’ ability to fully evaluate therapies.

To address this, DIA has launched the first phase of a global study to create the first standardized, patient-centered definition of treatment tolerability—one that combines clinical data with patient experience to better guide trial design, reporting, and patient care.


Read Press Release DIA Launches Research Study to Define Treatment Tolerability in Cancer Care

Bull Horn

Patient Voice

Tolerability isn’t just about side effects—it’s about whether patients can keep living their lives while on treatment .

DIA

What We’re Doing

Study Objectives

  1. Unify perspectives: Bring together clinicians, patients, and researchers to agree on a rigorous, patient-centered definition.
  2. Go beyond safety endpoints: Include factors like treatment logistics, symptom burden, and quality of life.
  3. Deliver practical tools: Recommend trial designs, analytical methods, and PRO (patient-reported outcome) measures to assess and compare tolerability across treatments.

Key Activities in Phase I

  • Literature review and conceptual model development
  • Direct input from patients and key opinion leaders (KOLs)
  • Identification of relevant PRO measures or gaps needing new tools
  • Analysis, reporting, and transparent dissemination of results

This phase will generate real-world evidence to improve patient–clinician conversations and support shared treatment decisions.


DIA Science Timeline


Explore Our Latest Projects

Ai in Healthcare

Data in Clinical Development

Learn More
Global Regulatory Cooperation

Regulatory Science

Learn More
Patient Engagement

Patient Engagement

Learn More
Value & Access

Value & Access

Learn More
Institutionalizing Innovation

Institutionalizing Innovation

Learn More

Learn More About Our Work

If you or your organization want to learn more about DIA’s Research projects or Think Tanks please contact Science@DIAglobal.org.

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.